Evidence map›Paper›PMID 28437734›Full record

ArticleDiabetes research and clinical practice2017

IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.

K Ogurtsova, J D da Rocha Fernandes, Y Huang, U Linnenkamp, L Guariguata, N H Cho, D Cavan, J E Shaw, L E Makaroff

6 registry-linked trialsAbstract readHistorical Article
PubMed Publisher
In one paragraph

Article in Diabetes research and clinical practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 1,761 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,761citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05037695 phase4unknown statusstarted 2021, after this paper: background citation

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)

Ran2021Enrolled40Registered outcomes17Posted comparisons0ConditionsAcute Kidney Injury, Coronary Artery Disease, Diabetes Mellitus, Type 2Armsempagliflozin 25 mg
Open the trial in the graph
NCT03898076 completednot on this mapstarted 2020, after this paper: background citation

The Prediction of A1c Based on CGM Data Through Applying Machine Learning Approaches

TypeobservationalSponsorSidra MedicineRan2020 to 2020Enrolled60ConditionsDiabetes Mellitus, Type 1ArmsFlash Glucose Monitoring, A1c, Predictive A1c
NCT04739254 suspendednot on this mapstarted 2020, after this paper: background citation

Magnetocardiography Endocrine Registry

TypeobservationalSponsorGenetesis Inc.Ran2020 to 2030Enrolled250ConditionsEndocrine DisorderArmsCardioFlux
NCT04790526 nacompletednot on this mapstarted 2021, after this paper: background citation

Dose Response of Eccentric Exercises on Glycemic Control in Type ii Diabetes Mellitus

TypeinterventionalSponsorRiphah International UniversityRan2021 to 2023Enrolled59ConditionsType II Diabetes MellitusArmsEccentric Exercises Dose
NCT05260281 unknown statusnot on this mapstarted 2022, after this paper: background citation

Performance Evaluation of Artificial Intelligence Assisted Diabetic Retinopathy Grading in the Leuven University Hospital: Can Technology Improve the Resident?

TypeobservationalSponsorUniversitaire Ziekenhuizen KU LeuvenRan2022 to 2022Enrolled139ConditionsTo Evaluate the Added Value of the Use of Artificial Intelligence in the Diagnosis of Referable Diabetic Retinopathy in a Teaching Hospital SettingArmsMONA algorithm
NCT05391659 naunknown statusnot on this mapstarted 2021, after this paper: background citation

E-CLAIR: Efficiency and Cost-effectiveness of Artificial Intelligence Based Diabetic Retinopathy Screening in Flanders

TypeinterventionalSponsorUniversitaire Ziekenhuizen KU LeuvenRan2021 to 2022Enrolled1,200ConditionsDiabetic RetinopathyArmsdeep learning, remote grading of fundus images, gold standard
3 · Its place in the literature

Who cites it

1,761 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Response to anti-VEGF injections for diabetic macular edema among patients on chronic exogenous insulin therapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1,701 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

K OgurtsovaInternational Diabetes Federation, Chaussee de la Hulpe 166, Brussels, Belgium.
J D da Rocha FernandesInternational Diabetes Federation, Chaussee de la Hulpe 166, Brussels, Belgium. Electronic address: joao.fernandes@idf.org.
Y HuangInternational Diabetes Federation, Chaussee de la Hulpe 166, Brussels, Belgium. Electronic address: yadi.huang@idf.org.
U LinnenkampInternational Diabetes Federation, Chaussee de la Hulpe 166, Brussels, Belgium.
L GuariguataInternational Diabetes Federation, Chaussee de la Hulpe 166, Brussels, Belgium. Electronic address: leonor.guariguata@gmail.com.
N H ChoInternational Diabetes Federation, Chaussee de la Hulpe 166, Brussels, Belgium; Department of Preventive Medicine, Ajou University School of Medicine, 164 World Cup-ro, Suwon, South Korea. Electronic address: chnaha@ajou.ac.kr.
D CavanInternational Diabetes Federation, Chaussee de la Hulpe 166, Brussels, Belgium. Electronic address: davidcavan@hotmail.com.
J E ShawBaker Heart and Diabetes Institute, 75 Commercial Rd, Melbourne, Australia. Electronic address: jonathan.shaw@bakeridi.edu.au.
L E MakaroffInternational Diabetes Federation, Chaussee de la Hulpe 166, Brussels, Belgium; Department of Microbiology and Immunology, University of Leuven, Herestraat 49, Leuven, Belgium. Electronic address: atlas@idf.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo produce current estimates of the national, regional and global impact of diabetes for 2015 and 2040.

methodsA systematic literature review was conducted to identify data sources on the prevalence of diabetes from studies conducted in the period from 1990 to 2015. An analytic hierarchy process was used to select the most appropriate studies for each country, and estimates for countries without data were modelled using extrapolation from similar countries that had available data. A logistic regression model was used to generate smoothed age-specific estimates, which were applied to UN population estimates.

results540 data sources were reviewed, of which 196 sources from 111 countries were selected. In 2015 it was estimated that there were 415 million (uncertainty interval: 340-536 million) people with diabetes aged 20-79years, 5.0 million deaths attributable to diabetes, and the total global health expenditure due to diabetes was estimated at 673 billion US dollars. Three quarters (75%) of those with diabetes were living in low- and middle-income countries. The number of people with diabetes aged 20-79years was predicted to rise to 642 million (uncertainty interval: 521-829 million) by 2040.

conclusionDiabetes prevalence, deaths attributable to diabetes, and health expenditure due to diabetes continue to rise across the globe with important social, financial and health system implications.

Indexed as

Global HealthAdultAgedDiabetes MellitusFemaleHistory, 21st CenturyHumansMaleMiddle AgedPrevalenceYoung AdultDiabetes mellitusEpidemiologyGestational diabetesHealth economicsImpaired glucose toleranceMortality

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.